BusinessSwitzerlandUK

Hail the antibody, cure with ease

27.03.2012 - The global private equity firm Celtic Therapeutic L.L.L.P. believes in the power of antibody-drug conjugates (ADCs). It is investing $50m in a new Switzerland-based company called ADC Therapeutics Sarl which takes off with ten proprietary ADC oncology programmes in the pipeline.

Among them are ADCs against prostate, lung, renal, breast and blood cancers. Bringing the cytotoxic therapeutics to the desired cancer cells with the help of antibodies has some advantages: ADCs are thought to be target-selective and highly potent. They have fewer side effects and could minimize drug resistance. "We believe that ADCs will represent a significant medical breakthrough in cancer therapy over the coming decade", says Celtic co-founder Stephen Evans-Freke. ADC Therapeutics can rely on the know-how of London's very own Spirogen, an ADC company controlled by Celtic. Spirogen's PBD (proprietary pyrrolobenzodiazepines) 'payload' technology constitutes, if anything, the 'best-in-class' ADC cytotoxic weapon ("warhead"). Scientific wisdom is also provided by British Cancer Research Technology Ltd as a shareholder and US-specialists Samuel Broder and Barrie Ward as non-executive directors. Celtic Therapeutics was founded in 2007 by Evans-Freke and Peter B. Corr, who retired from pharmaceutical giant Pfizer in 2006. Evans-Freke outlines the new company's strategy as follows: "The anticipated investment of up to $50 million into ADC Therapeutics will lead to clinical proof of concept in 2-3 lead oncology programmes. We are committed to fully fund ADC Therapeutics and will raise additional capital if warranted." After having resilient Phase II data promising ADCs could be then contracted to pharma giants.

FundingEU

17.04.2014 The European Parliament has given green light to the second Innovative Medicines Initiative with the aim to advance pharmacological research and development, particularly in areas of unmet medical need.

BusinessGermanyFrance

15.04.2014 German flavour and scent specialist Symrise has announced its plans to acquire French pet-food ingredients maker Diana Group for €1.3bn.

BioeconomySpain

14.04.2014 Spanish Neol Biosolutions and the Center for Second Generation Biofuels are starting a partnership to scale-up Neol's waste-to-oil technology.

EvidenceUKSwitzerland

11.04.2014 There is no evidence that neuraminidase inhibitors Tamiflu and Relenza prevent complications of influenza or reduce hospital admissions. In addition, it is unclear whether they can stop the spread of influenza in case of outbreaks, says a report by the Cochrane Collaboration.

BusinessSwitzerlandSpain

09.04.2014 Roche is extending its involvement in the area of point-of-care diagnostics by taking over US company Iquum. In the field of epigenetics, the Swiss pharma company has started a cooperation with the Spanish company Oryzon.

Status ReportSwitzerland

08.04.2014 The Swiss Biotech Report 2014 presented in Zurich sees an encouraging upturn in the country's biotech scene. However, the acceptance of the mass immigration initiative poses a significant threat.

NanobiotechnologyItaly

07.04.2014 Scientists from the University of Udine have designed, produced and tested a prototype for a "DNA origami" nanorobot that can potentially deliver biological activators in-vivo.

EpidemicEUFranceGermanyItaly

02.04.2014 As the Ebola epidemic in Guinea worsens, Europe is deploying the specialists of EMLab to provide diagnostics at the focus of the outbreak.

BioeconomyFranceEU

01.04.2014 The European Commission has approved a French state package aid worth €43m for green chemistry project IEED.

MonitoringEU

27.03.2014 In Europe, bacterial resistance to prevalent antimicrobials is common, while multi-resistance remains low, EFSA and ECDC now report.

Events

All Events

Partner-Events

München

BioVaria 2014

Frankfurt am Main

7th DVFA Life Science Conference

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • MORPHOSYS (D)62.00 EUR11.8%
  • BIOINVENT INTERNATIONAL AB (S)2.96 SEK10.9%
  • BAVARIAN NORDIC (D)14.56 EUR10.3%

FLOP

  • CYTOS (CH)0.17 CHF-26.1%
  • XENETIC BIOSCIENCES (UK)6.00 GBP-14.3%
  • FLAMEL TECHNOLOGIES (F)9.94 USD-9.7%

TOP

  • CO.DON (D)3.30 EUR88.6%
  • BIOTECH PHARMACON (N)17.50 NOK59.1%
  • WILEX (D)0.92 EUR50.8%

FLOP

  • CYTOS (CH)0.17 CHF-94.1%
  • BIONOR PHARMA (N)2.11 NOK-49.0%
  • GW PHARMACEUTICALS (UK)219.25 GBP-39.6%

TOP

  • SILENCE THERAPEUTICS (UK)256.00 GBP6143.9%
  • IXICO (UK)71.50 GBP807.4%
  • PLETHORA (UK)10.62 GBP585.2%

FLOP

  • CYTOS (CH)0.17 CHF-95.8%
  • EVOCUTIS (UK)0.22 GBP-92.7%
  • AGENNIX (D)0.04 EUR-80.0%

No liability assumed, Date: 16.04.2014